JP2020530844A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530844A5 JP2020530844A5 JP2020508022A JP2020508022A JP2020530844A5 JP 2020530844 A5 JP2020530844 A5 JP 2020530844A5 JP 2020508022 A JP2020508022 A JP 2020508022A JP 2020508022 A JP2020508022 A JP 2020508022A JP 2020530844 A5 JP2020530844 A5 JP 2020530844A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell
- tumor
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 43
- 201000011510 cancer Diseases 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 206010039491 Sarcoma Diseases 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 15
- 229940126264 SETD2 inhibitor Drugs 0.000 claims 11
- 208000009956 adenocarcinoma Diseases 0.000 claims 10
- 201000009030 Carcinoma Diseases 0.000 claims 7
- 108020004414 DNA Proteins 0.000 claims 7
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims 6
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 208000032839 leukemia Diseases 0.000 claims 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 201000004101 esophageal cancer Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- 201000003444 follicular lymphoma Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 3
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims 2
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 2
- 241000234671 Ananas Species 0.000 claims 2
- 235000007119 Ananas comosus Nutrition 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 108091033409 CRISPR Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 201000004458 Myoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 210000000941 bile Anatomy 0.000 claims 2
- 201000000053 blastoma Diseases 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims 2
- 230000003467 diminishing effect Effects 0.000 claims 2
- 201000008184 embryoma Diseases 0.000 claims 2
- 206010016629 fibroma Diseases 0.000 claims 2
- 230000003325 follicular Effects 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 238000010362 genome editing Methods 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 206010024627 liposarcoma Diseases 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000001817 pituitary effect Effects 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- -1 small molecule compound Chemical class 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 210000001635 urinary tract Anatomy 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 1
- 208000032248 Adenocarcinoma of the penis Diseases 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 1
- 108020004491 Antisense DNA Proteins 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004992 Bladder adenocarcinoma stage unspecified Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 206010005969 Bone giant cell tumour Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 201000000274 Carcinosarcoma Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010008583 Chloroma Diseases 0.000 claims 1
- 201000005262 Chondroma Diseases 0.000 claims 1
- 201000009047 Chordoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010009253 Clear cell sarcoma of the kidney Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 206010014714 Endocrine neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000033832 Eosinophilic Acute Leukemia Diseases 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 102400000321 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- 102000006947 Histones Human genes 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010025219 Lymphangioma Diseases 0.000 claims 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 206010064281 Malignant atrophic papulosis Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 206010029488 Nodular melanoma Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000007871 Odontogenic Tumors Diseases 0.000 claims 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 1
- 206010048757 Oncocytoma Diseases 0.000 claims 1
- 208000002063 Oxyphilic Adenoma Diseases 0.000 claims 1
- 101150012195 PREB gene Proteins 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 208000034541 Rare lymphatic malformation Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000025316 Richter syndrome Diseases 0.000 claims 1
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 206010041329 Somatostatinoma Diseases 0.000 claims 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 1
- 108020005202 Viral DNA Proteins 0.000 claims 1
- 108020000999 Viral RNA Proteins 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000004064 acoustic neuroma Diseases 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 claims 1
- 239000003816 antisense DNA Substances 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 201000006587 bladder adenocarcinoma Diseases 0.000 claims 1
- 201000011143 bone giant cell tumor Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000008274 breast adenocarcinoma Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 208000009667 cerebral sarcoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 210000004252 chorionic villi Anatomy 0.000 claims 1
- 208000030748 clear cell sarcoma of kidney Diseases 0.000 claims 1
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 201000000787 conjunctival cancer Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 210000003298 dental enamel Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- 210000002149 gonad Anatomy 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000006359 hepatoblastoma Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 210000003246 kidney medulla Anatomy 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 1
- 201000001117 malignant triton tumor Diseases 0.000 claims 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims 1
- 208000029586 mediastinal germ cell tumor Diseases 0.000 claims 1
- 208000030163 medullary breast carcinoma Diseases 0.000 claims 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 201000010225 mixed cell type cancer Diseases 0.000 claims 1
- 208000029638 mixed neoplasm Diseases 0.000 claims 1
- 208000022669 mucinous neoplasm Diseases 0.000 claims 1
- 201000009368 muscle benign neoplasm Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000005987 myeloid sarcoma Diseases 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 claims 1
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 1
- 201000000032 nodular malignant melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 208000027825 odontogenic neoplasm Diseases 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 208000027500 optic nerve neoplasm Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 208000003154 papilloma Diseases 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 208000024246 polyembryoma Diseases 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 208000037959 spinal tumor Diseases 0.000 claims 1
- 230000003393 splenic effect Effects 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000037964 urogenital cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023042770A JP2023082028A (ja) | 2017-08-14 | 2023-03-17 | Ｓｅｔｄ２を阻害することにより癌を処置する方法 |
| JP2025050879A JP2025094223A (ja) | 2017-08-14 | 2025-03-26 | Ｓｅｔｄ２を阻害することにより癌を処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545353P | 2017-08-14 | 2017-08-14 | |
| US62/545,353 | 2017-08-14 | ||
| PCT/US2018/046698 WO2019036466A1 (en) | 2017-08-14 | 2018-08-14 | METHODS OF TREATING CANCER BY INHIBITING SETD2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023042770A Division JP2023082028A (ja) | 2017-08-14 | 2023-03-17 | Ｓｅｔｄ２を阻害することにより癌を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530844A JP2020530844A (ja) | 2020-10-29 |
| JP2020530844A5 true JP2020530844A5 (https=) | 2021-09-16 |
Family
ID=65362451
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508022A Pending JP2020530844A (ja) | 2017-08-14 | 2018-08-14 | Ｓｅｔｄ２を阻害することにより癌を処置する方法 |
| JP2023042770A Pending JP2023082028A (ja) | 2017-08-14 | 2023-03-17 | Ｓｅｔｄ２を阻害することにより癌を処置する方法 |
| JP2025050879A Pending JP2025094223A (ja) | 2017-08-14 | 2025-03-26 | Ｓｅｔｄ２を阻害することにより癌を処置する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023042770A Pending JP2023082028A (ja) | 2017-08-14 | 2023-03-17 | Ｓｅｔｄ２を阻害することにより癌を処置する方法 |
| JP2025050879A Pending JP2025094223A (ja) | 2017-08-14 | 2025-03-26 | Ｓｅｔｄ２を阻害することにより癌を処置する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11952572B2 (https=) |
| EP (1) | EP3669279A4 (https=) |
| JP (3) | JP2020530844A (https=) |
| KR (1) | KR20200052294A (https=) |
| CN (2) | CN119405809A (https=) |
| AU (2) | AU2018318988A1 (https=) |
| CA (1) | CA3072746A1 (https=) |
| EA (1) | EA202090485A1 (https=) |
| IL (1) | IL272379B2 (https=) |
| MX (1) | MX2020001759A (https=) |
| SG (1) | SG11202000839TA (https=) |
| WO (1) | WO2019036466A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020530844A (ja) | 2017-08-14 | 2020-10-29 | エピザイム，インコーポレイティド | Ｓｅｔｄ２を阻害することにより癌を処置する方法 |
| CN112585119A (zh) | 2018-08-14 | 2021-03-30 | Epizyme股份有限公司 | 经取代的吲哚及其使用方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL63907A0 (en) | 1980-09-24 | 1981-12-31 | Cetus Corp | Diagnostic method and antibody probe for use therein |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| ATE53862T1 (de) | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4595766A (en) | 1984-10-26 | 1986-06-17 | Ciba-Geigy Corporation | Process for the preparation of an indoline carboxylic acid |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| US20040265929A1 (en) * | 2001-11-15 | 2004-12-30 | The Regents Of The University Of Michigan | Humoral response to HIP1 in cancer |
| US20040110802A1 (en) | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
| AU2003265382A1 (en) | 2002-08-23 | 2004-03-11 | Pharmacia & Upjohn Company Llc | Antibacterial benzoic acid derivatives |
| KR20080007649A (ko) | 2005-05-11 | 2008-01-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피페리딘환을 가지는 인돌 유도체의 결정 및 그의 제조방법 |
| RU2416603C9 (ru) | 2005-10-25 | 2012-06-20 | Сионоги Энд Ко., Лтд. | Производные аминодигидротиазина |
| US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
| US20100035862A1 (en) | 2008-06-25 | 2010-02-11 | Abbott Laboratories | Novel aza-cyclic indole-2-carboxamides and methods of use thereof |
| EP2330894B8 (en) | 2008-09-03 | 2017-04-19 | BioMarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
| US20110021362A1 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| CA2784894A1 (en) | 2009-12-23 | 2011-06-30 | Sanofi | Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors |
| US20130137748A1 (en) | 2010-02-03 | 2013-05-30 | Oncotherapy Science, Inc. | Whsc1 and whsc1l1 for target genes of cancer therapy and diagnosis |
| JP2012107001A (ja) | 2010-10-22 | 2012-06-07 | Shionogi & Co Ltd | インドールアミド化合物を含有する医薬 |
| WO2013063417A1 (en) * | 2011-10-27 | 2013-05-02 | Memorial Sloan-Kettering Cancer Center | Methyltransferase inhibitors for treating cancer |
| EP3119390A4 (en) | 2014-03-21 | 2017-09-20 | Glaxosmithkline Intellectual Property (No. 2) Limited | Methods of treating cancer |
| NZ725860A (en) | 2014-04-04 | 2019-08-30 | Iomet Pharma Ltd | Indole derivatives for use in medicine |
| WO2015164482A1 (en) | 2014-04-22 | 2015-10-29 | The Johns Hopkins University | Inhibitors of drug-resistant mycobacterium tuberculosis |
| US9902702B2 (en) | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| WO2016040505A1 (en) | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Smyd inhibitors |
| WO2016079321A1 (en) * | 2014-11-20 | 2016-05-26 | Cemm Forschungszentrum Für Molekulare Medizin Gmbh | Antagonists of setdb2 for use in the therapy of infectious diseases |
| WO2017106259A1 (en) * | 2015-12-17 | 2017-06-22 | Albert Einstein College Of Medicine, Inc. | Nuclear receptor set domain containing protein 2 transition state and uses thereof |
| CN106317043B (zh) | 2016-08-19 | 2018-11-02 | 成都理工大学 | 一种大麻素受体2激动剂 |
| JP2020530844A (ja) | 2017-08-14 | 2020-10-29 | エピザイム，インコーポレイティド | Ｓｅｔｄ２を阻害することにより癌を処置する方法 |
| CN112585119A (zh) | 2018-08-14 | 2021-03-30 | Epizyme股份有限公司 | 经取代的吲哚及其使用方法 |
| SG11202105325QA (en) | 2018-11-30 | 2021-06-29 | Epizyme Inc | Methods of treating whsc1-overexpressing cancers by inhibiting setd2 |
| WO2021168313A1 (en) | 2020-02-19 | 2021-08-26 | Epizyme, Inc. | Setd2 inhibitors and related methods and uses, including combination therapies |
| US20240299352A1 (en) | 2021-06-09 | 2024-09-12 | Epizyme, Inc. | Combination therapies with setd2 inhibitors |
| JP2024539726A (ja) | 2021-11-01 | 2024-10-29 | エピザイム，インコーポレイティド | Ｎ－（（１ｒ，３ｓ）－３－（４－アセチルピペラジン－１－イル）シクロヘキシル）－４－フルオロ－７－メチル－１ｈ－インドール－２－カルボキサミドの結晶形態 |
-
2018
- 2018-08-14 JP JP2020508022A patent/JP2020530844A/ja active Pending
- 2018-08-14 IL IL272379A patent/IL272379B2/en unknown
- 2018-08-14 CN CN202411561316.8A patent/CN119405809A/zh active Pending
- 2018-08-14 CA CA3072746A patent/CA3072746A1/en active Pending
- 2018-08-14 MX MX2020001759A patent/MX2020001759A/es unknown
- 2018-08-14 EA EA202090485A patent/EA202090485A1/ru unknown
- 2018-08-14 CN CN201880059329.1A patent/CN111094568A/zh active Pending
- 2018-08-14 KR KR1020207007131A patent/KR20200052294A/ko not_active Ceased
- 2018-08-14 WO PCT/US2018/046698 patent/WO2019036466A1/en not_active Ceased
- 2018-08-14 SG SG11202000839TA patent/SG11202000839TA/en unknown
- 2018-08-14 US US16/639,424 patent/US11952572B2/en active Active
- 2018-08-14 AU AU2018318988A patent/AU2018318988A1/en not_active Abandoned
- 2018-08-14 EP EP18846764.1A patent/EP3669279A4/en active Pending
-
2023
- 2023-03-17 JP JP2023042770A patent/JP2023082028A/ja active Pending
-
2025
- 2025-02-14 AU AU2025201027A patent/AU2025201027A1/en active Pending
- 2025-03-26 JP JP2025050879A patent/JP2025094223A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yadav et al. | Cancer stem cells: acquisition, characteristics, therapeutic implications, targeting strategies and future prospects | |
| Zhang et al. | Expressions of nuclear factor κB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome | |
| Selvakumaran et al. | Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy | |
| US20200332300A1 (en) | Multi-target modulation for treating fibrosis and inflammatory conditions | |
| CN105378083B (zh) | 修饰的TGF-β寡核苷酸 | |
| Drygin et al. | Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer | |
| JP6340162B2 (ja) | アポトーシス誘導剤 | |
| CN112007161B (zh) | Cdca8在制备治疗卵巢癌药物中的应用 | |
| JP2011506343A (ja) | トポイソメラーゼ阻害剤とｐａｒｐ阻害剤との組み合わせによるがんの治療 | |
| JP6667967B2 (ja) | Ｍｅｔ阻害剤に対する感受性予測用の新規なバイオマーカー及びその用途 | |
| Sheng et al. | MicroRNA-429 decreases the invasion ability of gastric cancer cell line BGC-823 by downregulating the expression of heparanase | |
| JP2020530844A5 (https=) | ||
| RU2014142057A (ru) | Комплексная терапия | |
| Liu et al. | Long non-coding RNA XIST promotes hepatocellular carcinoma progression by sponging miR-200b-3p. | |
| Yang et al. | Clinical and biological significance of hepatoma‐derived growth factor in Ewing's sarcoma | |
| CN104623663B (zh) | 评估癌症于治疗后情况的方法及其相关应用 | |
| US11110182B2 (en) | Multifunctional RNA nanoparticles and methods for treating cancer and therapeutic resistant cancer | |
| JPWO2019189772A1 (ja) | 長鎖ノンコーディングｒｎａを標的とするがん治療剤およびがん診断方法 | |
| WO2015194522A1 (ja) | アポトーシス誘導剤 | |
| Chen et al. | DJ‐1/FGFR‐1 signaling pathway contributes to sorafenib resistance in hepatocellular carcinoma | |
| Qin et al. | piRNA28846 has the potential to be a novel RNA nucleic acid drug for ovarian cancer | |
| Chen et al. | Inhibiting lncRNA NEAT1 facilitates the sensitization of melanoma cells to cisplatin through modulating the miR-519c-3p-MeCP2 axis | |
| CN117018204A (zh) | 一种治疗癌症的组合物及其应用和药物 | |
| Qi et al. | The METTL3/TGF-β1 signaling axis promotes osteosarcoma progression by inducing MSC differentiation into CAFs via m6A modification | |
| CN114099684B (zh) | miR-32-5p在制备提高肿瘤细胞对双氢青蒿素敏感性的药物中的应用 |